CA2247848C - Nitric oxide donors capable of reducing toxicity from drugs - Google Patents

Nitric oxide donors capable of reducing toxicity from drugs Download PDF

Info

Publication number
CA2247848C
CA2247848C CA002247848A CA2247848A CA2247848C CA 2247848 C CA2247848 C CA 2247848C CA 002247848 A CA002247848 A CA 002247848A CA 2247848 A CA2247848 A CA 2247848A CA 2247848 C CA2247848 C CA 2247848C
Authority
CA
Canada
Prior art keywords
drug
use according
formula
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002247848A
Other languages
English (en)
French (fr)
Other versions
CA2247848A1 (en
Inventor
Piero Del Soldato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11373387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2247848(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nicox SA filed Critical Nicox SA
Publication of CA2247848A1 publication Critical patent/CA2247848A1/en
Application granted granted Critical
Publication of CA2247848C publication Critical patent/CA2247848C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Underground Structures, Protecting, Testing And Restoring Foundations (AREA)
  • Medicinal Preparation (AREA)
CA002247848A 1996-02-26 1997-02-24 Nitric oxide donors capable of reducing toxicity from drugs Expired - Fee Related CA2247848C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT96MI000352A IT1282686B1 (it) 1996-02-26 1996-02-26 Composti in grado di ridurre la tossicita' da farmaci
ITMI96A000352 1996-02-26
PCT/EP1997/000873 WO1997031654A1 (en) 1996-02-26 1997-02-24 Nitric oxide donors capable of reducing toxicity from drugs

Publications (2)

Publication Number Publication Date
CA2247848A1 CA2247848A1 (en) 1997-09-04
CA2247848C true CA2247848C (en) 2008-07-15

Family

ID=11373387

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002247848A Expired - Fee Related CA2247848C (en) 1996-02-26 1997-02-24 Nitric oxide donors capable of reducing toxicity from drugs

Country Status (16)

Country Link
US (1) US7087588B2 (enExample)
EP (2) EP0904110B1 (enExample)
JP (1) JP2000506133A (enExample)
KR (1) KR19990087113A (enExample)
AT (1) ATE220920T1 (enExample)
AU (1) AU706591B2 (enExample)
BR (1) BR9707739A (enExample)
CA (1) CA2247848C (enExample)
DE (1) DE69714253T2 (enExample)
DK (1) DK0904110T3 (enExample)
ES (1) ES2180938T3 (enExample)
HU (1) HUP9900993A3 (enExample)
IT (1) IT1282686B1 (enExample)
PT (1) PT904110E (enExample)
RU (1) RU2192247C2 (enExample)
WO (1) WO1997031654A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
GB9801398D0 (en) 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
IT1298338B1 (it) * 1998-03-05 1999-12-20 Nicox Sa Composizioni farmaceutiche per l'ulcera
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
JP2003523958A (ja) 1999-12-23 2003-08-12 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法
AU2001234602A1 (en) * 2000-01-26 2001-08-07 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
US7211561B2 (en) 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
WO2003088961A1 (en) 2002-04-19 2003-10-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
US7220749B2 (en) 2002-06-11 2007-05-22 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP2005535642A (ja) 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
JP2005539089A (ja) 2002-07-03 2005-12-22 ニトロメッド インコーポレーティッド ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法
CA2493156A1 (en) 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
SE0300971D0 (sv) * 2003-04-03 2003-04-03 Aga Ab Nitric oxide in treatment of inflammation
AU2005206227A1 (en) * 2004-01-27 2005-08-04 Merck Frosst Company Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
US20080039521A1 (en) * 2004-06-10 2008-02-14 Hiroyasu Yasuda Anticancer Effect Enhancer
JP2007325501A (ja) * 2004-08-25 2007-12-20 Tottori Univ 非ステロイド性抗炎症薬による動物の消化管副作用の予防・治療方法
EP2669269B1 (en) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US20100240745A1 (en) * 2009-03-20 2010-09-23 Nicox S.A. Method of treatment of inflammation in hypertensive patients
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
RU2539630C1 (ru) * 2013-07-09 2015-01-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемии сетчатки в эксперименте

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5570683A (en) 1990-12-05 1996-11-05 The General Hospital Corporation Methods and devices for treating pulmonary vasoconstriction and asthma
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
IT1256450B (it) 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
JP3775796B2 (ja) 1993-10-06 2006-05-17 ニコックス エス エイ 抗炎症活性及び／又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法
RU2145595C1 (ru) 1994-05-10 2000-02-20 Никокс С.А. Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5620416A (en) 1995-06-07 1997-04-15 North Carolina State University Methods of using topical agents with systemically administered active agents

Also Published As

Publication number Publication date
DK0904110T3 (da) 2002-11-11
KR19990087113A (ko) 1999-12-15
BR9707739A (pt) 1999-07-27
CA2247848A1 (en) 1997-09-04
AU706591B2 (en) 1999-06-17
ITMI960352A0 (enExample) 1996-02-26
RU2192247C2 (ru) 2002-11-10
US20040242651A1 (en) 2004-12-02
JP2000506133A (ja) 2000-05-23
IT1282686B1 (it) 1998-03-31
AU2092497A (en) 1997-09-16
ES2180938T3 (es) 2003-02-16
US7087588B2 (en) 2006-08-08
WO1997031654A1 (en) 1997-09-04
DE69714253T2 (de) 2003-03-06
PT904110E (pt) 2002-12-31
EP0904110A1 (en) 1999-03-31
HUP9900993A3 (en) 2000-10-30
DE69714253D1 (de) 2002-08-29
EP0904110B1 (en) 2002-07-24
EP1221326A3 (en) 2004-01-14
HUP9900993A2 (hu) 1999-09-28
ITMI960352A1 (it) 1997-08-26
ATE220920T1 (de) 2002-08-15
EP1221326A2 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
EP0904110B1 (en) Nitric oxide donors capable of reducing toxicity from drugs
Ignarro Nitric oxide as a unique signaling molecule in the
Walker Jr et al. Methods of reduction of cisplatin nephrotoxicity
Iadecola et al. Nitric oxide synthase inhibition and cerebrovascular regulation
ES2215305T3 (es) Metodos analgesicos usando los catalizadores sinteticos para la dismutacion de los radicales superoxido.
Hao et al. Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered nitric oxide synthase inhibitors
US5554638A (en) Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
RU98117618A (ru) Донорные окиси азота, способные снижать токсичность от лекарственных препаратов
Grutzner et al. Effect of injury on pulpal levels of immunoreactive substance P and immunoreactive calcitonin gene-related peptide
JP2026040780A (ja) 腸炎および／または肝炎を治療および／または予防するための薬剤および食品
US20020049157A1 (en) Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
CN1198669A (zh) 氨基金刚烷类化合物作为免疫调节剂的用途
JPH10194978A (ja) 一酸化窒素産生抑制剤
Southerland et al. Dual enkephalinase inhibitors and their role in chronic pain management
US20090221473A1 (en) Antitumor agents
FAST et al. Antibiotic therapy in the management of hepatic coma
Satterwhite et al. Pharmacokinetics of ketoprofen in rats: effect of age and dose
JPH02500368A (ja) 温血動物における腫瘍阻止方法
ES2314056T3 (es) Activadores de la anhidrasa carbonica para mejorar el aprendizaje y la memoria.
CN117503911A (zh) 治疗血友病的药物组合物及用途
Caner et al. Effects of orlistat and its relationship with nitric oxide in the small intestinal mucosa
Khanderia et al. Acute intermittent porphyria: pathophysiology and treatment
Murphy et al. Hemodynamic effects of the renin inhibitor CP-80,794 in several species
Malin et al. Nitric oxide synthesis inhibition attenuates behavioral actions of neuropeptide FF
PT1042286E (pt) Compostos imunomoduladores contendo grupos gama-glutamilo e beta-aspartilo e métodos para os preparar

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20120224